Denver, Colo. - Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient ...
Radioisotope therapy uses radioactive medicines to treat some cancer types. The radioisotope travels around your body in the bloodstream to the area where the cancer is. The radioactive part is called ...
Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...
For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6. Median overall survival was 79 months, but 32 percent of the ...
PRRT can also be effective for patients with nongastroenteropancreatic tumors, such as non-radioiodine-avid thyroid carcinoma and paraganglioma; however, further studies are needed to determine PRRT's ...
A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC) No significant financial relationships to disclose. This is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results